Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 234 mg (equivalent: paliperidone, qty 150 mg) - injection - excipient ingredients: monobasic sodium phosphate monohydrate; citric acid monohydrate; water for injections; polysorbate 20; macrogol 4000; dibasic sodium phosphate; sodium hydroxide - invega sustenna is indicated for the acute and maintenance treatment of schizophrenia in adults.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 78 mg (equivalent: paliperidone, qty 50 mg) - injection - excipient ingredients: macrogol 4000; polysorbate 20; water for injections; citric acid monohydrate; dibasic sodium phosphate; sodium hydroxide; monobasic sodium phosphate monohydrate - invega sustenna is indicated for the acute and maintenance treatment of schizophrenia in adults.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - bortezomib, quantity: 1 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - - velcade, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. - velcade, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. - velcade is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. - velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - fentanyl, quantity: 2.1 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethylene/vinyl acetate copolymer; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative care, and other conditions in patients where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - fentanyl, quantity: 16.8 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethylene/vinyl acetate copolymer; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative care, and other conditions in patients where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - fentanyl, quantity: 12.6 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethylene/vinyl acetate copolymer; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative care, and other conditions in patients where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - fentanyl, quantity: 8.4 mg - drug delivery system, transdermal - excipient ingredients: ethylene/vinyl acetate copolymer; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative care, and other conditions in patients where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - fentanyl, quantity: 4.2 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethylene/vinyl acetate copolymer; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative care, and other conditions in patients where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - - velcade, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. - velcade, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. - velcade is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. - velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - infliximab, quantity: 100 mg - injection, powder for - excipient ingredients: dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate; polysorbate 80; sucrose - rheumatoid arthritis in adults: remicade, in combination with methotrexate, is indicated for the reduction of signs and symptoms and prevention of structural joint damage (erosions and joint space narrowing) in: patients with active disease despite treatment with methotrexate; patients with active disease who have not previously received methotrexate. remicade should be given in combination with methotrexate. efficacy and safety in rheumatoid arthritis have been demonstrated only in combination with methotrexate. ankylosing spondylitis: remicade is indicated for the reduction of signs and symptoms and improvement in physical function in patients with active disease. psoriatic arthritis: remicade is indicated for the treatment of the signs and symptoms, as well as for the improvement in physical function in adult patients with active and progressive psoriatic arthritis who have responded inadequately to disease-modifying anti-rheumatic drug (dmard) therapy. remicade may be administered in combination with methotrexate. psoriasis: remicade is indicated for the treatment of adult patients with moderate to severe plaque psoriasis for whom phototherapy or conventional systemic treatments have been inadequate or are inappropriate. safety and efficacy beyond 12 months have not been established. crohn's disease in adults and in children and adolescents (6-17 years): remicade is indicated for the treatment of moderate to severe crohn's disease, to reduce the signs and symptoms and to induce and maintain clinical remission in patients who have an inadequate response to conventional therapies. refractory fistulising crohn's disease: remicade is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients. ulcerative colitis in adults and in children and adolescents (6 to 17 years); remicade is indicated for the treatment of moderately severe to severe active ulcerative colitis in patients who have had an inadequate response to conventional therapy.